Loading
OPB-401 is an experimental in vivo CAR T-cell therapy from Outpace Bio, in preclinical development for B-cell lymphomas.
OPB-401 is an in vivo CAR T-cell therapy from Outpace Bio. An in vivo CAR-T programme against CD19 and CD20; the source gives no further detail. Its furthest stage is preclinical development, for B-cell lymphomas. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.
1.OPB-401 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OPB-401" OR ABSTRACT:"OPB-401") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OPB-401, not a curated reading list.
Shares Outpace Bio and the tag pipeline.
Shares Outpace Bio and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Outpace Bio and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/